Hepion Pharmaceuticals Expands SAB with Appointments of Four Liver Disease KOLs
EDISON, N.J., March 30, 2023 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage…
Month: March 2023
Hepion Pharmaceuticals Expands SAB with Appointments of Four Liver Disease KOLs
EDISON, N.J., March 30, 2023 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage…
AIM ImmunoTech Bolsters Board of Directors with Appointment of Pharmaceutical Industry Veteran Nancy K. Bryan, with Deep Commercial, Marketing, Business Development and Corporate Finance Expertise
Nancy K. Bryan Nancy K. Bryan OCALA, Fla., March 30, 2023 (GLOBE NEWSWIRE) — AIM…
AIM ImmunoTech Bolsters Board of Directors with Appointment of Pharmaceutical Industry Veteran Nancy K. Bryan, with Deep Commercial, Marketing, Business Development and Corporate Finance Expertise
Nancy K. Bryan Nancy K. Bryan OCALA, Fla., March 30, 2023 (GLOBE NEWSWIRE) — AIM…
NurExone Announces Q4 and Full-year 2022 Financial Results and Provides Company Update, Highlighting 143.9% Scientific Research Investment Growth
TORONTO and TEL AVIV, Israel, March 30, 2023 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (the…
NurExone Announces Q4 and Full-year 2022 Financial Results and Provides Company Update, Highlighting 143.9% Scientific Research Investment Growth
TORONTO and TEL AVIV, Israel, March 30, 2023 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (the…
Sofwave™ Wins 2023 NewBeauty Award For Best Non-Invasive Cellulite Treatment
This year’s award is successive to last year’s recognition as NewBeauty’s winner for “Best in…
Sofwave™ Wins 2023 NewBeauty Award For Best Non-Invasive Cellulite Treatment
This year’s award is successive to last year’s recognition as NewBeauty’s winner for “Best in…
Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
— Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series…
Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
— Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series…
Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report
Report Highlights Company’s Mission to Democratize Patient Access to CAR T While Maintaining Focus on…
Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report
Report Highlights Company’s Mission to Democratize Patient Access to CAR T While Maintaining Focus on…
Dyadic to Present at World Vaccine Congress Washington 2023
JUPITER, Fla., March 30, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”)…
Dyadic to Present at World Vaccine Congress Washington 2023
JUPITER, Fla., March 30, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”)…
MedAvail Postpones Reporting of Fourth Quarter and FY 2022 Financial Results
PHOENIX, March 30, 2023 (GLOBE NEWSWIRE) — MedAvail Holdings, Inc. (NASDAQ: MDVL) (“MedAvail” or the…
MedAvail Postpones Reporting of Fourth Quarter and FY 2022 Financial Results
PHOENIX, March 30, 2023 (GLOBE NEWSWIRE) — MedAvail Holdings, Inc. (NASDAQ: MDVL) (“MedAvail” or the…
Inventiva announces filing of its 2022 Universal Registration Document and 2022 Annual Report on Form 20-F
Daix (France), Long Island City (New York, United States), March 30, 2023 Inventiva (Euronext Paris…
Inventiva announces filing of its 2022 Universal Registration Document and 2022 Annual Report on Form 20-F
Daix (France), Long Island City (New York, United States), March 30, 2023 Inventiva (Euronext Paris…
IMUNON Reports 2022 Financial Results and Provides Business Update
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 30, 2023 (GLOBE…
Rumi Scientific Appoints Allen A. Fienberg, Ph.D., as Chief Executive Officer and Chairman of the Board of Directors
NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) — Rumi Scientific (“Rumi”), a developer of therapies…